Merus (NASDAQ:MRUS) Upgraded to “Hold” by StockNews.com

Merus (NASDAQ:MRUSGet Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other brokerages also recently issued reports on MRUS. William Blair reissued an “outperform” rating on shares of Merus in a research report on Monday, April 22nd. Stifel Nicolaus upped their price objective on shares of Merus from $40.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Needham & Company LLC restated a “buy” rating and issued a $66.00 price target on shares of Merus in a research note on Monday. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Merus in a research note on Thursday, May 9th. Finally, BMO Capital Markets upped their price target on Merus from $49.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, February 29th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Merus currently has a consensus rating of “Moderate Buy” and an average target price of $56.33.

View Our Latest Stock Analysis on MRUS

Merus Price Performance

MRUS stock traded down $1.08 during midday trading on Tuesday, reaching $44.77. The company had a trading volume of 589,606 shares, compared to its average volume of 609,291. Merus has a 1 year low of $19.81 and a 1 year high of $52.03. The company has a market capitalization of $2.63 billion, a P/E ratio of -16.16 and a beta of 1.10. The firm has a 50-day moving average price of $44.64 and a 200-day moving average price of $36.14.

Merus (NASDAQ:MRUSGet Free Report) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. The company had revenue of $7.89 million for the quarter, compared to analysts’ expectations of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. On average, equities analysts predict that Merus will post -3.31 EPS for the current year.

Institutional Trading of Merus

A number of large investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC grew its holdings in shares of Merus by 37.7% in the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 343 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Merus by 142.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after buying an additional 867 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Merus by 64.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 828 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Merus in the 1st quarter valued at about $72,000. Finally, SG Americas Securities LLC purchased a new position in Merus in the first quarter worth about $108,000. Institutional investors own 96.14% of the company’s stock.

Merus Company Profile

(Get Free Report)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

Read More

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.